Mallinckrodt to sell BioVectra for $250 million

10 September 2019

Heavily involved in US opioid crisis lawsuit settlements, UK-incorporated Mallinckrodt (NYSE: MNK) today announced it has entered into a definitive agreement to sell its wholly-owned subsidiary BioVectra to an affiliate of private equity firm HIG Capital.

The transaction price is around $250 million, including fixed consideration of $175 million, comprised of an upfront payment of $135 million and a long-term note for $40 million, and contingent payments of up to $75 million, enabling Mallinckrodt to capture future BioVectra growth potential.

News of the deal saw Mallinckrodt’s shares rise 12.6% to $2.37 in pre-market trading this morning. The stock has plummeted 77.9% over the past three months, amid concerns that federal opioid litigation has caused the company to consider filing for bankruptcy, which the drugmaker has downplayed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK